Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Few at-risk women are willing to take tamoxifen prophylactically
May 5th, 2005
Fewer than one in five women eligible to take tamoxifen were inclined to take the drug after being told of its risks and benefits, according to a new study. Researchers said the concerns over the drug's adverse effects were the primary reason for refusal. The study is scheduled for print publication in the May 15, 2005, issue of Cancer. It appeared online April 11, 2005. Tamoxifen, a synthetic estrogen receptor modulator (SERM), is an effective breast cancer adjuvant therapy and is also recognized as a breast cancer prevention drug for women. It has the added benefit of reducing the risk of osteoporotic fractures. ...
Source: Women's Health Weekly (2005-05-05)
|
